| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
9,550,000 |
| Market
Cap: |
18.15(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.39 - $3.41 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Checkpoint Therapeutics is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of treatments for patients with solid tumor cancers. Co. is evaluating its primary antibody product candidate, cosibelimab, an anti-programmed death-ligand 1 antibody, in an ongoing global, open-label, multicohort clinical trial in checkpoint therapy-naive patients with selected recurrent or metastatic cancers. Co. is also evaluating its main small-molecule, targeted anti-cancer agent, olafertinib, an epidermal growth factor receptor (EGFR) inhibitor, as a potential treatment for patients with EGFR mutation-positive non-small cell lung cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
23,944 |
23,944 |
335,570 |
| Total Sell Value |
$0 |
$48,297 |
$48,297 |
$531,878 |
| Total People Sold |
0 |
2 |
2 |
2 |
| Total Sell Transactions |
0 |
4 |
4 |
16 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gray William Garrett |
See Remarks |
• – – |
2020-05-21 |
4 |
S |
$2.00 |
$34,122 |
D/D |
(17,104) |
359,896 |
|
-28% |
|
| Gray William Garrett |
See Remarks |
• – – |
2020-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
157,000 |
377,000 |
|
- |
|
| Oliviero James F Iii |
CEO, President and Director |
• • – |
2020-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
598,000 |
2,733,000 |
|
- |
|
| Rosenwald Lindsay A Md |
Director |
– • – |
2019-11-20 |
4 |
B |
$1.27 |
$127,000 |
D/D |
100,000 |
237,890 |
2.39 |
- |
|
| Weiss Michael S |
Director |
– • – |
2019-06-13 |
4 |
A |
$0.00 |
$0 |
I/I |
11,442 |
37,890 |
|
- |
|
| Salzman Barry M |
Director |
– • – |
2019-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
11,442 |
87,890 |
|
- |
|
| Rosenwald Lindsay A Md |
Director |
– • – |
2019-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
11,442 |
137,890 |
|
- |
|
| Bechon Christian |
Director |
– • – |
2019-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
11,442 |
61,442 |
|
- |
|
| Herskowitz Neil |
Director |
– • – |
2019-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
11,442 |
87,890 |
|
- |
|
| Boilen Scott |
Director |
– • – |
2019-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
11,442 |
110,112 |
|
- |
|
| Oliviero James F Iii |
CEO, President and Director |
• • – |
2019-01-24 |
4 |
A |
$0.00 |
$0 |
D/D |
485,000 |
2,135,000 |
|
- |
|
| Gray William Garrett |
See Remarks |
• – – |
2019-01-24 |
4 |
A |
$0.00 |
$0 |
D/D |
90,000 |
220,000 |
|
- |
|
| Rosenwald Lindsay A Md |
Director |
– • – |
2018-11-09 |
4 |
B |
$2.35 |
$116,715 |
D/D |
49,666 |
126,448 |
2.39 |
- |
|
| Rosenwald Lindsay A Md |
Director |
– • – |
2018-11-08 |
4 |
B |
$2.24 |
$108,044 |
D/D |
48,234 |
76,782 |
2.39 |
- |
|
| Rosenwald Lindsay A Md |
Director |
– • – |
2018-11-07 |
4 |
B |
$2.12 |
$4,452 |
D/D |
2,100 |
28,548 |
2.31 |
- |
|
| Herskowitz Neil |
Director |
– • – |
2018-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
16,448 |
76,448 |
|
- |
|
| Salzman Barry M |
Director |
– • – |
2018-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
16,448 |
76,448 |
|
- |
|
| Boilen Scott |
Director |
– • – |
2018-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
16,448 |
98,670 |
|
- |
|
| Weiss Michael S |
Director |
– • – |
2018-06-14 |
4 |
A |
$0.00 |
$0 |
I/I |
16,448 |
26,448 |
|
- |
|
| Rosenwald Lindsay A Md |
Director |
– • – |
2018-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
16,448 |
26,448 |
|
- |
|
| Gray William Garrett |
See Remarks |
• – – |
2018-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
130,000 |
|
- |
|
| Oliviero James F Iii |
CEO and President |
• – – |
2018-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
325,000 |
1,650,000 |
|
- |
|
| Rosenwald Lindsay A Md |
Director |
– • – |
2017-07-10 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
10,000 |
|
- |
|
| Boilen Scott |
Director |
– • – |
2017-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
82,222 |
|
- |
|
| Salzman Barry M |
Director |
– • – |
2017-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
60,000 |
|
- |
|
111 Records found
|
|
Page 4 of 5 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.01 (0.53%) 
